drugset
drugset / Trial / NCT04505397

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

NCT04505397 ↗

Phase 1 Completed 111 enrolled SK Life Science, Inc. Covance · collabSpaulding Clinical Research LLC · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This study evaluates SKL24741 safety and tolerability in healthy subjects. Subjects will be randomized to receive oral doses of SKL24741 or placebo. This is a two-part, double-blinded, randomized study of SKL24741.

Timeline

Start
2020-02-13
Primary completion
2022-10-27
Completion
2022-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject SKL24741 Unknown 10 mg Oral
Subject SKL24741 Unknown 25 mg Oral
Subject SKL24741 Unknown 50 mg Oral
Subject SKL24741 Unknown 100 mg Oral
Subject SKL24741 Unknown 200 mg Oral
Subject SKL24741 Unknown 300 mg Oral
Subject SKL24741 Unknown 400 mg Oral
Subject SKL24741 Unknown 800 mg Oral
Subject SKL24741 Unknown 1200 mg Oral
Subject SKL24741 Unknown 2000 mg Oral

Indications

No indication recorded.